采用甲泼尼龙、巴瑞替尼和瑞德西韦成功治疗1例合并帕博利珠单抗诱导性关节炎的肺癌患者的重症新型冠状病毒肺炎。
Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.
作者信息
Oda Naohiro, Miyoshi Keiji, Morichika Daisuke, Beika Yuka, Taki Takahiro, Mitani Reo, Okada Toshiaki, Takata Ichiro
机构信息
Department of Internal Medicine Fukuyama City Hospital Fukuyama Japan.
Department of Respiratory Medicine Fukuyama Medical Center Fukuyama Japan.
出版信息
Clin Case Rep. 2021 Jul 6;9(7):e04459. doi: 10.1002/ccr3.4459. eCollection 2021 Jul.
COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.
正在使用免疫抑制剂治疗免疫检查点抑制剂免疫相关不良事件的癌症患者感染新型冠状病毒肺炎（COVID-19）后病情可能迅速恶化。甲泼尼龙、巴瑞替尼和瑞德西韦联合治疗对于重症COVID-19可能有效，有必要开展进一步的临床试验。
Zotero 插件